In addition, some tumors prompt regulatory T cells (Tregs) to express CTLA-4, leading to downregulation of CD80/CD86 expression in antigen-presenting cells, resulting in reduced production of cytokines such as interleukin 2, which affects the body’s anti-tumor capacity (66). Here, CD86 is linked to neoplasm.